Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 11/20 | 0.44 |
| ▸ | CA1 | P00915 | 10/20 | 0.44 |
| ▸ | CA9 | Q16790 | 9/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 4/20 | 0.43 |
| ▸ | CA7 | P43166 | 4/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.43 |
| ▸ | CA3 | P07451 | 2/20 | 0.43 |
| ▸ | CA4 | P22748 | 2/20 | 0.43 |
| ▸ | CA6 | P23280 | 2/20 | 0.43 |
| ▸ | CA5A | P35218 | 2/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27670053 | 0.95 | CA2 (0.46) | RECQLTSHRGLAHPGDMAPK1 | |
| SCHEMBL27995614 | 0.89 | RECQL (0.57) | RECQLTSHRGLAHPGDMAPK1 | |
| SCHEMBL27520719 | 0.89 | RECQL (0.57) | RECQLTSHRGLAHPGDMAPK1 | |
| SCHEMBL19809912 | 0.87 | L3MBTL1 (0.45) | TSHRMAPK1CA2CA1CA9 | |
| SCHEMBL27550478 | 0.87 | RECQL (0.55) | RECQLTSHRGLAHPGDMAPK1 | |
| SCHEMBL283871 | 0.84 | MCHR1 (0.47) | RECQLTSHRGLAHPGDMAPK1 | |
| SCHEMBL15000837 | 0.83 | MEN1 (0.46) | CA2CA1CA9CA12CA7 | |
| SCHEMBL5015857 | 0.83 | RECQL (0.50) | RECQLTSHRGLAHPGDMAPK1 | |
| SCHEMBL10725263 | 0.83 | RECQL (0.50) | RECQLTSHRGLAHPGDMAPK1 | |
| SCHEMBL2194649 | 0.83 | RECQL (0.50) | RECQLTSHRGLAHPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5602228-A | Nickel phosphate catalysts | MAXDEM INCORPORATED (US) | 1997-02-11 | — | — | US | claimed |
| WO-1996039455-A1 | NICKEL PHOSPHITE CATALYSTS | MAXDEM INCORPORATED (US) | 1996-12-12 | — | — | WO | claimed |
| US-20130045993-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES AND THEIR USE | Piramal Enterprises Limited (IN) | 2013-02-21 | — | — | US | disclosed |
| US-8304449-B2 | Inhibitors of cyclin dependent kinases and their use | PIRAMAL HEALTHCARE LIMITED (IN) | 2012-11-06 | — | — | US | disclosed |
| US-20110136873-A1 | Inhibitors of Cyclin Dependent Kinases and Their Use | PIRAMAL LIFE SCIENCES LTD. (IN) | 2011-06-09 | — | — | US | disclosed |
| US-7915301-B2 | chromenone derivatives of nitrogen-, oxygen- or sulfur-containing saturated heterocycles; preparation by cyclizing benzoyl intermediates; antiproliferative agents; 2-(2-Chloro-phenyl)-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl)-5,7-dimethoxy-chromen-4-one | Piramal Life Science Limited (IN) | 2011-03-29 | — | — | US | disclosed |
| EP-1556375-B1 | FLAVONE DERIVATIVES AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | NICHOLAS PIRAMAL INDIA LTD (IN) | 2008-06-25 | — | — | EP | disclosed |
| US-20080108690-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASES AND THEIR USE | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2008-05-08 | — | — | US | disclosed |
| US-7271193-B2 | Inhibitors of cyclin-dependent kinases and their use | NICHOLAS PIRAMAL INDIA, LTD. (IN) | 2007-09-18 | — | — | US | disclosed |
| US-20040106581-A1 | Inhibitors of cyclin-dependent kinases and their use | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2004-06-03 | — | — | US | disclosed |
| US-5858907-A | Nickel phosphite catalysts | MAXDEM, INCORPORATED (US) | 1999-01-12 | — | — | US | disclosed |
| US-5602228-A | Nickel phosphate catalysts | MAXDEM INCORPORATED (US) | 1997-02-11 | — | — | US | disclosed |
| WO-1996039455-A1 | NICKEL PHOSPHITE CATALYSTS | MAXDEM INCORPORATED (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106581-A1 | Inhibitors of cyclin-dependent kinases and their use | CCNK, CCNI, CDK1 | RECQL 297/4885TSHR 2892/4885GLA 2999/4885 |
| US-20080108690-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASES AND THEIR USE | CDK1, CCNK, CCNI | RECQL 195/4885TSHR 2164/4885GLA 3399/4885 |
| US-20110136873-A1 | Inhibitors of Cyclin Dependent Kinases and Their Use | CDK1, CCNK, CCNI | RECQL 195/4885TSHR 2164/4885GLA 3399/4885 |
| US-20130045993-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES AND THEIR USE | CDK1, CCNK, CCNI | RECQL 263/4885TSHR 1950/4885GLA 3661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.